Rockwell Medical (RMTI) 10-Q 16 May 22 2022 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 13, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	000-23661
Entity Registrant Name	ROCKWELL MEDICAL, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	38-3317208
Entity Address, Address Line One	30142 S. Wixom Road
Entity Address, City or Town	Wixom
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	48393
City Area Code	248
Local Phone Number	960-9009
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of 12(b) Security	Common Stock, par value $0.0001
Trading Symbol	RMTI
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding (in shares)		8,532,478
Entity Central Index Key	0001041024
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
ASSETS
Cash and Cash Equivalents	$ 9,914	$ 13,280
Investments Available-for-Sale	0	9,158
Accounts Receivable, net	7,121	5,913
Inventory, net	5,531	4,076
Prepaid and Other Current Assets	2,231	2,861
Total Current Assets	24,797	35,288
Property and Equipment, net	2,377	2,486
Inventory, Non-Current	1,523	1,523
Right of Use Assets, net	7,200	7,737
Goodwill	921	921
Other Non-Current Assets	618	619
Total Assets	37,436	48,574
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
Accounts Payable	4,224	3,739
Accrued Liabilities	4,373	5,090
Lease Liability - Current	1,983	2,004
Deferred License Revenue - Current	2,163	2,171
Term Loan - Net of Issuance Costs	6,631	7,381
Insurance Financing Note Payable	0	437
Customer Deposits	221	144
Total Current Liabilities	19,595	20,966
Lease Liability - Long-Term	5,400	5,887
Term Loan, Net of Issuance Costs	11,778	13,186
Deferred License Revenue - Long-Term	5,456	5,986
Long Term Liability - Other	14	14
Total Liabilities	42,243	46,039
Stockholders’ (Deficit) Equity:
Preferred Stock, $0.0001 par value, 2,000,000 shares authorized; no shares issued and outstanding at March 31, 2022 and December 31, 2021	0	0
Common Stock, $0.0001 par value; 170,000,000 shares authorized; 8,544,225 shares issued and outstanding at March 31, 2022 and December 31, 2021	1	1
Additional Paid-in Capital	372,383	372,562
Accumulated Deficit	(377,242)	(370,080)
Accumulated Other Comprehensive Income	51	52
Total Stockholders’ (Deficit) Equity	(4,807)	2,535
Total Liabilities and Stockholders’ Equity	$ 37,436	$ 48,574

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred shares, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred shares, shares authorized (in shares)	2,000,000	2,000,000
Preferred shares, shares issued (in shares)	0	0
Preferred shares, shares outstanding (in shares)	0	0
Common shares, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common shares, shares authorized (in shares)	170,000,000	170,000,000
Common shares, shares issued (in shares)	8,544,225	8,544,225
Common shares, shares outstanding (in shares)	8,544,225	8,544,225

UNAUDITED CONDENSED CONSOLIDATE

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Net Sales	$ 16,124	$ 15,473
Cost of Sales	16,910	15,072
Gross (Loss) Profit	(786)	401
Research and Product Development	1,567	1,809
Selling and Marketing	455	1,851
General and Administrative	3,818	3,923
Operating Loss	(6,626)	(7,182)
Other (Expense) Income
Realized Gain on Investments	4	0
Interest Expense	(540)	(581)
Interest Income	0	11
Total Other Expense	(536)	(570)
Net Loss	$ (7,162)	$ (7,752)
Basic Net Loss per Share (in dollars per share)	$ (0.84)	$ (0.91)
Diluted Net Loss per Share (in dollars per share)	$ (0.84)	$ (0.91)
Basic Weighted Average Shares Outstanding (in shares)	8,544,225	8,508,278
Diluted Weighted Average Shares Outstanding (in shares)	8,544,225	8,508,278

UNAUDITED CONDENSED CONSOLIDA_2

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement of Comprehensive Income [Abstract]
Net Loss	$ (7,162)	$ (7,752)
Unrealized Gain (Loss) on Available-for-Sale Debt Instrument Investments	0	(7)
Foreign Currency Translation Adjustments	(1)	3
Comprehensive Loss	$ (7,163)	$ (7,756)

UNAUDITED CONDENSED CONSOLIDA_3

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	COMMON STOCK	ADDITIONAL PAID-IN CAPITAL	ACCUMULATED DEFICIT	ACCUMULATED OTHER COMPREHENSIVE INCOME
Beginning balance (in shares) at Dec. 31, 2020		8,506,651
Beginning balance at Dec. 31, 2020	$ 34,170	$ 1	$ 371,518	$ (337,406)	$ 57
Increase (Decrease) in Shareholders' Equity
Net Loss	(7,752)			(7,752)
Unrealized Gain (Loss) on Available-for-Sale Debt Instrument Investments	(7)				(7)
Foreign Currency Translation Adjustments	3				3
Stock-based Compensation expense (in shares)		2,396
Stock-based Compensation expense	(236)		(236)
Ending balance (in shares) at Mar. 31, 2021		8,509,047
Ending balance at Mar. 31, 2021	$ 26,178	$ 1	371,282	(345,158)	53
Beginning balance (in shares) at Dec. 31, 2021	8,544,225	8,544,225
Beginning balance at Dec. 31, 2021	$ 2,535	$ 1	372,562	(370,080)	52
Increase (Decrease) in Shareholders' Equity
Net Loss	(7,162)			(7,162)
Unrealized Gain (Loss) on Available-for-Sale Debt Instrument Investments	0
Foreign Currency Translation Adjustments	(1)				(1)
Stock-based Compensation expense (in shares)		0
Stock-based Compensation expense	$ (179)		(179)
Ending balance (in shares) at Mar. 31, 2022	8,544,225	8,544,225
Ending balance at Mar. 31, 2022	$ (4,807)	$ 1	$ 372,383	$ (377,242)	$ 51

UNAUDITED CONDENSED CONSOLIDA_4

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash Flows From Operating Activities:
Net Loss	$ (7,162)	$ (7,752)
Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:
Depreciation and Amortization	138	202
Stock-based Compensation	(179)	(236)
Increase in Inventory Reserves	0	71
Amortization of Right of Use Asset	520	412
Amortization of Debt Financing Costs and Accretion of Debt Discount	92	92
Loss on Disposal of Assets	0	6
Realized Gain on Sale of Investments Available-for-Sale	(4)	0
Foreign Currency Translation Adjustment	(1)	3
Changes in Assets and Liabilities:
Increase in Accounts Receivable, net	(1,208)	(2,426)
Increase in Inventory	(1,455)	(424)
Decrease in Prepaid and Other Assets	630	317
Increase (Decrease) in Accounts Payable	485	(848)
Decrease in Lease Liability	(490)	(410)
Decrease in Other Liabilities	(640)	(958)
Decrease in Deferred License Revenue	(538)	(544)
Changes in Assets and Liabilities	(3,216)	(5,293)
Cash Used In Operating Activities	(9,812)	(12,495)
Cash Flows From Investing Activities:
Purchase of Investments Available-for-Sale	(2,810)	(7,212)
Sale of Investments Available-for-Sale	11,972	6,738
Purchase of Equipment	(29)	(38)
Cash Provided By (Used In) Investing Activities	9,133	(512)
Cash Flows From Financing Activities:
Payments on Debt	(2,250)	0
Payments on Short Term Note Payable	(437)	0
Cash Used In Financing Activities	(2,687)	0
Decrease in Cash and Cash Equivalents	(3,366)	(13,007)
Cash and Cash Equivalents at Beginning of Period	13,280	48,682
Cash and Cash Equivalents at End of Period	9,914	35,675
Supplemental Disclosure of Cash Flow Information:
Cash Paid for Interest	461	485
Supplemental Disclosure of Noncash Investing and Financing Activities:
Change in Unrealized Loss on Marketable Securities Available-for-Sale	$ 0	$ (7)

Description of Business

Description of Business	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business Rockwell Medical, Inc. ("Rockwell Medical," "Rockwell", or the "Company") is a commercial-stage, biopharmaceutical company developing and commercializing our next-generation parenteral iron technology platform, ferric pyrophosphate citrate (“FPC”), which we believe has significant potential to lead to transformative treatments for iron deficiency in multiple disease states, that we believe could reduce healthcare costs and improve patients’ lives. We are also one of the two major suppliers of life saving hemodialysis concentrate products to kidney dialysis clinics in the United States. We have two novel, FDA approved therapies, Triferic and Triferic AVNU, which are the first two products developed from our FPC platform. We market both products to kidney dialysis centers for their patients receiving dialysis. In late 2021, we filed an IND with the United States Food and Drug Administration ("FDA") with the goal to advance our FPC platform strategy by conducting a Phase II trial for the treatment of iron deficiency anemia in patients outside of dialysis, who are receiving intravenous ("IV") medications in the home infusion setting. The trend toward providing medical care, including the delivery of infused medications, at home make the home infusion market a rapidly growing area of healthcare. We believe the home infusion setting is a natural path for expansion of our platform as many of the patients suffer from diseases associated with iron deficiency and anemia. In our R&D pipeline, we are also investigating FPC’s impact in the treatment of hospitalized patients with acute heart failure. We are the second largest supplier of hemodialysis concentrates in the United States, with a reputation for excellent service, quality, and reliability. We believe this reputation, which is based on over 25 years of service to kidney dialysis centers, combined with about $60 million in annual revenue, approximately 300 dedicated employees, expertise in manufacturing and logistics and the added expertise in pharmaceutical development and commercialization brought to the Company by recent additions to our management team, gives us a solid foundation on which to grow.

Liquidity and Going Concern Con

Liquidity and Going Concern Considerations	3 Months Ended
	Mar. 31, 2022
Liquidity and Going Concern Considerations [Abstract]
Liquidity and Going Concern Considerations	Liquidity and Going Concern Considerations Since inception, the Company has incurred significant net losses and has funded its operations primarily through revenue from commercial products, proceeds from the issuance of debt and equity securities and payments from partnerships. At March 31, 2022, Rockwell had an accumulated deficit of approximately $377.2 million and a stockholders' deficit of $4.8 million. As of March 31, 2022, Rockwell had approximately $9.9 million of cash and cash equivalents and working capital of $5.2 million. Net cash used in operating activities for the three months ended March 31, 2022 was approximately $9.8 million. The Company has experienced significant inflationary pressures in its dialysis concentrates business, particularly within the last six months, which have resulted in an accelerated operating loss associated with this business line. These factors raise substantial doubt about the Company’s ability to continue as a going concern and depend, in part, on the degree of success in the Company's ability to address inflationary pressures affecting the concentrates business, as well as the Company’s ability to contain costs, raise additional working capital and remain in compliance with financial and operating covenants under the Company’s secured loan. Managements plans are described below. On April 6, 2022, the Company entered into an amendment to one of its supply agreements to restructure the supply relationship, which management expects to result in improved financial performance of the Company's concentrate business. The Company also entered into an equity investment agreement with one of the contracting parties for an investment of up to $15 million in two tranches of $7.5 million each. The first tranche of $7.5 million was funded on April 7, 2022. The second $7.5 million tranche is to be funded subject to the Company raising $15 million in additional capital by June 30, 2022. On April 8, 2022, the Company entered into a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may offer and sell from time to time up to $12,200,000 of shares of Company’s common stock through the Agent. The offering and sale of such shares has been registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-259923) (the “Registration Statement”), which was originally filed with the Securities and Exchange Commission (“SEC”) on September 30, 2021 and declared effective by the SEC on October 8, 2021, the base prospectus contained within the Registration Statement, and a prospectus supplement that was filed with the SEC on April 8, 2022. The Company has started to implement cost cutting measures as noted in previous filings focusing mainly within sales and marketing. The Company expects it will require additional capital to sustain its operations and make the investments it needs to execute its strategic plan in developing FPC for iron deficiency anemia in patients undergoing home infusion and for progressing our pipeline development program of new indications for our FPC platform. If the Company is unable to generate sufficient cash flows from operations as described above or obtain additional equity or debt financing, the Company intends to implement further cost cutting measure which may include headcount reduction across multiple areas and reductions in general and administrative expenses. Based on these plans, Management believes the substantial doubt about the Company’s ability to continue as a going concern has been alleviated. If the Company attempts to obtain additional debt or equity financing, the Company cannot assume that such financing will be available on favorable terms, if at all. Currently, because the Company's public float is less than $75 million, we are subject to the baby shelf limitations under our current registration statement on Form S-3, which limit the amount we may offer under our Form S-3. This could limit our ability to raise capital under this registration statement. As previously reported, on June 11, 2021, the Company received written notice (the "Notification Letter") from the Nasdaq Stock Market ("Nasdaq") notifying the Company that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities maintain a minimum closing bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum closing bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's common stock for the 30 consecutive business days prior to the date of the Notification Letter, the Company did not meet the minimum closing bid price requirement. The Notification Letter provided for 180 calendar days, or until December 8, 2021, for the Company to regain compliance with Nasdaq Listing Rule 5450(a)(1). To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of 10 consecutive business days at any time prior to December 8, 2021. The Company was not able to meet the minimum compliance requirements set forth by Nasdaq by December 8, 2021. On December 9, 2021, the Company received a written notice from Nasdaq indicating that the Company’s application to transfer its listing venue from The Nasdaq Global Market to The Nasdaq Capital Market for its common stock had been approved. The Company’s common stock commenced trading on The Nasdaq Capital Market at the opening of business on December 10, 2021 under the symbol “RMTI.” Also on December 9, 2021, the Company received written notice that Nasdaq has determined the Company is eligible for an additional 180-day extension, or until June 6, 2022, to regain compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of 10 consecutive business days at any time prior to June 6, 2022. On May 13, 2022, the Company effected a reverse stock split in order to regain compliance with the minimum bid price requirement (see Note 3 for further detail). In addition, the Company is subject to certain covenants and cure provisions under its Loan Agreement with Innovatus. As of the date of this report, the Company believes it will either be able to satisfy such covenants or, in the event of a breached covenant, exercise cure provisions to avoid an event of default. If Rockwell is unable to avoid an event of default, any required repayments could have an adverse effect on its liquidity (See Note 14 for further detail). The COVID-19 pandemic and resulting global disruptions, particularly in the supply chain and labor market, among other areas, have adversely affected our business and operations, including, but not limited to, our sales and marketing efforts and our research and development activities, our plant and transportation operations and the operations of third parties upon whom we rely. Further, any vaccine hesitancy among our labor force could disrupt our business if workers become ill or need to quarantine due to illness or exposure to the virus. The Company's international business development activities may also continue to be negatively impacted by COVID-19. The COVID-19 pandemic, the domestic and international surge in infections and resulting global disruptions have caused significant volatility in financial and credit markets. Rockwell has utilized a range of financing methods to fund its operations in the past; however, current conditions in the financial and credit markets may limit the availability of funding, refinancing or increase the cost of funding. Due to the rapidly evolving nature of the global situation, it is not possible to predict the extent to which these conditions could adversely affect the Company's liquidity and capital resources in the future.

Basis of Presentation, Summary

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements	Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting PronouncementsThe accompanying condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U. S. Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. The condensed consolidated balance sheet at March 31, 2022, condensed consolidated statements of operations for the three months ended March 31, 2022 and 2021, condensed consolidated statements of comprehensive loss for the three months ended March 31, 2022 and 2021, condensed consolidated statement of changes in stockholders' equity for the three months ended March 31, 2022 and 2021, and condensed consolidated statements of cash flows for the three months ended March 31, 2022 and 2021 are unaudited, but include all adjustments, consisting of normal recurring adjustments, the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three months ended March 31, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022 or for any future interim period. The condensed consolidated balance sheet at December 31, 2021 has been derived from audited financial statements, however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2021 and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 as filed with the SEC on April 8, 2022. The Company’s consolidated subsidiaries consisted of its wholly-owned subsidiaries, Rockwell Transportation, Inc. and Rockwell Medical India Private Limited. The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation. Reverse Stock Split On May 9, 2022, the stockholders of the Company authorized our Board of Directors to effect a reverse stock split of all outstanding shares of common stock. The Board of Directors subsequently approved the implementation of a reverse stock split as a ratio of one-for-eleven shares, which became effective on May 13, 2022. The Company’s outstanding stock options were also adjusted to reflect the one-for-eleven reverse stock split of the Company’s common stock. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The reverse stock split resulted in an adjustment to the Series X convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. All share and per share data in these condensed consolidated financial statements and related notes hereto have been retroactively adjusted to the account for the effect of the reverse stock split for the three month periods ended March 31, 2022 and 2021, respectively, and the balance sheet at March 31, 2022 and December 31, 2021. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Leases The Company accounts for its leases under Accounting Standards Codification (“ASC”) 842, Leases . Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred. In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term. Loss Per Share ASC 260, Earnings Per Share , requires dual presentation of basic and diluted earnings per share (“EPS”), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity. Basic net loss per share of common stock excludes dilution and is computed by dividing the net loss by the weighted average number of shares outstanding during the period. Diluted net loss per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. The Company has only incurred losses, therefore, basic and diluted net loss per share is the same. Securities that could potentially dilute net income per share in the future that were not included in the computation of diluted loss per share were as follows: As of March 31, 2022 2021 Options to purchase common stock 511,117 558,417 Unvested restricted stock awards 891 7,118 Unvested restricted stock units 28,067 21,611 Warrants to purchase common stock 2,402,442 2,402,442 Total 2,942,517 2,989,588 Adoption of Recent Accounting Pronouncements The Company continually assesses new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures that there are sufficient controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition The Company recognizes revenue under ASC 606, Revenue from Contracts with Customers. The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle: • Step 1: Identify the contract with the customer • Step 2: Identify the performance obligations in the contract • Step 3: Determine the transaction price • Step 4: Allocate the transaction price to the performance obligations in the contract • Step 5: Recognize revenue when the company satisfies a performance obligation Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight related to contracts with customers are accounted for as a fulfillment cost and are included in cost of sales when control of the goods transfers to the customer. Nature of goods and services The following is a description of principal activities from which the Company generates its revenue. Product sales – The Company accounts for individual products and services separately if they are distinct (i.e., if a product or service is separately identifiable from other items and if a customer can benefit from it on its own or with other resources that are readily available to the customer). The consideration, including any discounts, is allocated between separate products and services based on their stand-alone selling prices. The stand-alone selling prices are determined based on the cost plus margin approach. Drug and dialysis concentrate products are sold directly to dialysis clinics and to wholesale distributors in both domestic and international markets. Distribution and license agreements for which upfront fees are received are evaluated upon execution or modification of the agreement to determine if the agreement creates a separate performance obligation from the underlying product sales. For all existing distribution and license agreements, the distribution and license agreement is not a distinct performance obligation from the product sales. In instances where regulatory approval of the product has not been established and the Company does not have sufficient experience with the foreign regulatory body to conclude that regulatory approval is probable, the revenue for the performance obligation is recognized over the term of the license agreement (over time recognition). Conversely, when regulatory approval already exists or is probable, revenue is recognized at the point in time that control of the product transfers to the customer. The Company received upfront fees under five distribution and license agreements that have been deferred as a contract liability. The amounts received from Wanbang Biopharmaceuticals Co., Ltd. (“Wanbang”), Sun Pharmaceutical Industries Ltd. ("Sun Pharma"), Jeil Pharmaceutical Co., Ltd. ("Jeil Pharma") and Drogsan Pharmaceuticals ("Drogsan Pharma") are recognized as revenue over the estimated term of the applicable distribution and license agreement as regulatory approval was not received and the Company did not have sufficient experience in China, India, South Korea and Turkey, respectively, to determine that regulatory approval was probable as of the execution of the agreement. The amounts received from Baxter Healthcare Corporation (“Baxter”) are recognized as revenue at the point in time that the estimated product sales under the agreement occur. For the business under the Company’s Distribution Agreement with Baxter (the “Baxter Agreement”) and for the majority of the Company’s international customers, the Company recognizes revenue at the shipping point, which is generally the Company’s plant or warehouse. For other business, the Company recognizes revenue based on when the customer takes control of the product. The amount of revenue recognized is based on the purchase order less returns and adjusted for any rebates, discounts, chargebacks or other amounts paid to customers. There were no such adjustments for the periods reported. Customers typically pay for the product based on customary business practices with payment terms averaging 30 days, while distributor payment terms average 45 days. Disaggregation of revenue Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. In thousands of U.S. dollars ($) Three Months Ended March 31, 2022 Products By Geographic Area Total U.S. Rest of World Drug Revenues Product Sales – Point-in-time $ 159 $ 159 $ — License Fee – Over time 62 — 62 Total Drug Products 221 159 62 Concentrate Products Product Sales – Point-in-time 15,427 13,810 1,617 License Fee – Over time 476 476 — Total Concentrate Products 15,903 14,286 1,617 Net Revenue $ 16,124 $ 14,445 $ 1,679 In thousands of U.S. dollars ($) Three Months Ended March 31, 2021 Products By Geographic Area Total U.S. Rest of World Drug Revenues Product Sales – Point-in-time $ 225 $ 225 $ — License Fee – Over time 58 — 58 Total Drug Products 283 225 58 Concentrate Products Product Sales – Point-in-time 14,705 13,201 1,504 License Fee – Over time 485 485 — Total Concentrate Products 15,190 13,686 1,504 Net Revenue $ 15,473 $ 13,911 $ 1,562 Contract balances The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers. In thousands of U.S. dollars ($) March 31, 2022 December 31, 2021 Receivables, which are included in "Trade and other receivables" $ 7,121 $ 5,913 Contract liabilities $ 7,619 $ 8,157 There were no impairment losses recognized related to any receivables arising from the Company’s contracts with customers for the three months ended March 31, 2022 and 2021. For the three months ended March 31, 2022 and March 31, 2021, the Company did not recognize any material bad-debt expense. There were no material contract assets recorded on the condensed consolidated balance sheet as of March 31, 2022 and December 31, 2021. The Company does not generally accept returns of its concentrate products and no material reserve for returns of concentrate products was established as of March 31, 2022 or December 31, 2021. The contract liabilities primarily relate to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products Transaction price allocated to remaining performance obligations For the three months ended March 31, 2022, revenue recognized from performance obligations related to prior periods was not material. Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, totaled $7.6 million as of March 31, 2022. The amount relates primarily to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products. The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The Baxter Agreement includes minimum commitments of product sales over the duration of the agreement. Unfulfilled minimum commitments related to the Baxter Agreement are product sales of $4.8 million as of March 31, 2022, which is amortized ratably through expiration of the Baxter Agreement on October 2, 2024.

Investments - Available-for-Sal

Investments - Available-for-Sale	3 Months Ended
	Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Investments - Available-for-Sale	Investments - Available-for-Sale As of March 31, 2022, all investment available-for-sale securities have been liquidated. Investments available-for-sale consisted of the following as of December 31, 2021 (table in thousands): December 31, 2021 Amortized Cost Unrealized Gain Unrealized Loss Accrued Interest Fair Value Available-for-Sale Securities Bonds $ 9,143 $ 1 $ — $ 14 $ 9,158 The fair value of investments available-for-sale are determined using quoted market prices from daily exchange-traded markets based on the closing price as of the balance sheet date and are classified as a Level 1 measurement under ASC 820 Fair Value Measurements. As of December 31, 2021, the amortized cost and estimated fair value of our available-for-sale securities were due within one year.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Inventory	Inventory Components of inventory, net of reserves, as of March 31, 2022 and December 31, 2021 are as follows (table in thousands): March 31, December 31, Raw Materials $ 4,312 $ 3,434 Work in Process 408 201 Finished Goods 2,334 1,964 Total $ 7,054 $ 5,599 As of March 31, 2022, the Company classified $1.5 million of inventory as non-current, all of which was related to Triferic or the active pharmaceutical ingredient and raw materials for Triferic. As of March 31, 2022, the total Triferic inventory net of reserve was $1.6 million. The $1.6 million net value of Triferic inventory consisted of $0.3 million of Triferic (dialysate) finished goods with expiration dates ranging from July 2022 to December 2023, $0.4 million of Triferic API with an estimated useful life extending through 2023, and $0.9 million of raw materials for Triferic with an estimated useful life of 25 years.

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment As of March 31, 2022 and December 31, 2021, the Company’s property and equipment consisted of the following (table in thousands): March 31, December 31, Leasehold Improvements $ 1,204 $ 1,204 Machinery and Equipment 5,867 5,864 Information Technology & Office Equipment 1,845 1,845 Laboratory Equipment 660 676 9,576 9,589 Accumulated Depreciation (7,199) (7,103) Property and Equipment, net $ 2,377 $ 2,486

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued Liabilities Accrued liabilities as of March 31, 2022 and December 31, 2021 consisted of the following (table in thousands): March 31, December 31, Accrued Research & Development Expense $ 338 $ 366 Accrued Compensation and Benefits 1,158 1,791 Accrued Unvouchered Receipts 537 796 Accrued Workers Compensation 458 382 Other Accrued Liabilities 1,882 1,755 Total Accrued Liabilities $ 4,373 $ 5,090

Deferred Revenue

Deferred Revenue	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Deferred Revenue	Deferred Revenue In October 2014, the Company entered into the Baxter Agreement, which has a term of 10 years and received an upfront fee of $20 million. The upfront fee was recorded as deferred revenue and is being recognized based on the proportion of product shipments to Baxter in each period, compared with total expected sales volume over the term of the Distribution Agreement. The Company recognized revenue of approximately $0.5 million for each of the three months ended March 31, 2022 and 2021. Deferred revenue related to the Baxter Agreement totaled $4.8 million as of March 31, 2022 and $5.2 million as of December 31, 2021. In 2016, the Company entered into a distribution agreement with Wanbang (the "Wanbang Agreement") and received an upfront fee of $4.0 million. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $0.1 million during each of the three months ended March 31, 2022 and 2021. Deferred revenue related to the Wanbang Agreement totaled $2.5 million as of March 31, 2022 and December 31, 2021. In January 2020, the Company entered into license and supply agreements with Sun Pharma (the "Sun Pharma Agreements"), for the rights to commercialize Triferic (dialysate) (ferric pyrophosphate citrate) in India. Under the terms of the Sun Pharma Agreements, Sun Pharma will be the exclusive development and commercialization partner for Triferic (dialysate) in India, and the Company will supply the product to Sun Pharma. In consideration for the license, the Company received an upfront fee of $0.1 million, and will be eligible for milestone payments and royalties on net sales. A Joint Alliance Committee, comprised of members from the Company and Sun Pharma, will guide the development and execution for Triferic (dialysate) in India. Sun Pharma will be responsible for all clinical and regulatory approval, as well as commercialization activities. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $2,500 for each of the three months ended March 31, 2022 and 2021. Deferred revenue related to the Sun Pharma Agreement totaled $77,500 and $80,000 as of March 31, 2022 and December 31, 2021, respectively. In September 2020, the Company entered into a license and supply agreements with Jeil Pharma (the "Jeil Pharma Agreements"), for the rights to commercialize Triferic (dialysate) (ferric pyrophosphate citrate) in South Korea. Under the terms of the Jeil Pharma Agreements, Jeil Pharma will be the exclusive development and commercialization partner for Triferic (dialysate) in South Korea, and the Company will supply the product to Jeil Pharma. In consideration for the license, the Company received an upfront fee of $0.2 million, and will be eligible for milestone payments and royalties on net sales. A Joint Alliance Committee, comprised of members from the Company and Jeil Pharma, will guide the development and execution for Triferic (dialysate) in South Korea. Jeil Pharma will be responsible for all clinical and regulatory approval, as well as commercialization activities. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of $2,500 for each of the three months ended March 31, 2022 and 2021. Deferred revenue related to the Jeil Pharma Agreement totaled approximately $0.2 million as of March 31, 2022 and December 31, 2021. In June 2021, the Company entered into license and supply agreements with Drogsan Pharma (the "Drogsan Agreements"), for the rights to commercialize Triferic (dialysate) and Triferic AVNU in Turkey. Under the terms of the

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity Preferred Stock On April 6, 2022, the Company and DaVita Inc. ("DaVita") entered into a Securities Purchase Agreement (the "SPA"), pursuant to which the Company will issue up to $15 million of preferred stock to DaVita. On April 6, 2022, the Company issued 7,500 shares of a newly designated series of preferred stock, which is designated “Series X Convertible Preferred Stock” (the "Series X Preferred Stock") for gross proceeds of $7.5 million. The Company will issue an additional 7,500 shares of Series X Preferred Stock to DaVita in a second closing (the "Second Tranche") for an additional $7.5 million if the Company raises $15 million in additional capital by June 30, 2022. The Series X Preferred Stock will be issued for a price $1,000 per share (the "Face Amount"), subject to accretion at a rate of 1% per annum, compounded annually. If the Company’s common stock trades above $22.00 for a period of 30 calendar days, the accretion will thereafter cease. The Series X Convertible Preferred Stock is convertible to common stock at rate equal to the Face Amount, divided by a conversion price of $11.00 per share (subject to adjustment for stock splits, reverse stock splits and similar recapitalization events). As a result, each share of Series X Preferred Stock will initially convert into approximately 91 shares of common stock. DaVita’s right to convert to common stock is subject to a beneficial ownership limitation, which is initially set at 9.9% of the outstanding common stock, which limitation may be reset (not to exceed 19.9%) at DaVita’s option and upon providing prior written notice to the Company. The shares issued in the Second Tranche will have a lower conversion price if the Company raises capital through the issuance of convertible preferred stock prior to the closing of the Second Tranche and the conversion price of the securities sold in such preferred stock offerings is below $11.00 per share. In addition, any debt financing is limited by the terms of our Securities Purchase Agreement with DaVita. Specifically, until DaVita owns less than 50% of its investment, the Company may only incur additional debt in the form of a purchase money loan, a working capital line of up to $5 million or to refinance existing debt, unless DaVita consents. As of March 31, 2022 and December 31, 2021, there were 2,000,000 shares of preferred stock, $0.0001 par value per share, authorized and no shares of preferred stock issued and outstanding. Common Stock As of March 31, 2022 and December 31, 2021, there were 170,000,000 shares of common stock, $0.0001 par value per share, authorized and 8,544,225 and 8,544,225 shares issued and outstanding, respectively.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based CompensationThe Company recognized total stock-based compensation expense during the three months ended March 31, 2022 and 2021 as follows (table in thousands): Three Months Ended 2022 2021 Service-based awards: Restricted stock units $ 12 $ 104 Stock option awards 200 391 212 495 Performance-based awards: Restricted stock awards (391) (391) Stock option awards — (340) (391) (731) Total $ (179) $ (236) Restricted Stock A summary of the Company’s restricted stock awards during the three months ended March 31, 2022 is as follows: Number of Shares Weighted Average Unvested at January 1, 2022 7,118 $ 62.70 Forfeited (6,227) $ 62.70 Unvested at March 31, 2022 891 $ 62.70 A summary of the Company’s restricted stock awards during the three months ended March 31, 2021 is as follows: Number of Shares Weighted Average Unvested at January 1, 2021 13,345 $ 62.70 Forfeited (6,227) $ 62.70 Unvested at March 31, 2021 7,118 $ 62.70 The fair value of restricted stock awards are measured based on their fair value on the date of grant and amortized over the vesting period of 20 months. As of March 31, 2022, unvested restricted stock awards of 891 were related to performance-based awards. The forfeited performance-based restricted stock awards of 6,227 was due to the resignation of the Company's Chief Development Officer on March 25, 2022. These forfeited awards reduced stock-based compensation expense by $0.4 million. Service-Based Restricted Stock Units A summary of the Company’s service-based restricted stock units during the three months ended March 31, 2022 is as follows: Number of Shares Weighted Average Unvested at January 1, 2022 29,289 $ 12.87 Forfeited (1,223) 52.91 Unvested at March 31, 2022 28,066 $ 11.11 A summary of the Company’s service-based restricted stock units during the three months ended March 31, 2021 is as follows: Number of Shares Weighted Average Unvested at January 1, 2021 24,136 $ 28.60 Granted 914 22.99 Vested (1,042) 52.91 Forfeited (2,396) 27.50 Unvested at March 31, 2021 21,612 $ 27.39 The fair value of service based restricted stock units are measured based on their fair value on the date of grant and amortized over the vesting period. The vesting periods range from 1 to 3 years. Stock-based compensation expense of $12,000 and $104,000 was recognized for the three months ended March 31, 2022 and 2021, respectively. As of March 31, 2022, the unrecognized stock-based compensation expense was $0.1 million, which is expected to be recognized over an estimated weighted average remaining term of less than 1 year. Service-Based Stock Options The fair value of the service-based stock options granted for the three months ended March 31, 2022 were based on the following assumptions: March 31, Exercise price $4.12 Expected stock price volatility 76.2% Risk-free interest rate 1.98% Term (years) 6.5 A summary of the Company’s service-based stock option activity for the three months ended March 31, 2022 is as follows: Shares Weighted Weighted Aggregate Outstanding at January 1, 2022 528,591 $ 32.01 7.5 $ — Granted 909 4.07 9.9 — Forfeited (14,839) 17.49 — — Expired (3,545) 85.36 — — Outstanding at March 31, 2022 511,116 $ 32.01 7.0 $ 1 Exercisable at March 31, 2022 236,720 $ 52.14 5.0 $ — A summary of the Company’s service-based stock option activity for the three months ended March 31, 2021 is as follows: Shares Weighted Weighted Aggregate Outstanding at January 1, 2021 519,814 $ 50.05 6.6 $ — Granted 7,672 17.60 6.0 — Forfeited (16,721) 27.39 — — Expired (20,530) 84.26 — — Outstanding at March 31, 2021 490,235 $ 48.95 6.1 $ — Exercisable at March 31, 2021 251,180 $ 73.48 3.2 $ — The aggregate intrinsic value in the table above is calculated as the difference between the closing price of the Company's common stock and the exercise price of the stock options that had strike prices below the closing price. During the three months ended March 31, 2022, the Company granted stock options to purchase up to 909 shares of common stock to certain employees. During the three months ended March 31, 2022, 14,839 shares were forfeited and 3,545 shares expired. Forfeitures are recorded in the period of occurrence; compensation expense is adjusted accordingly. Stock-based compensation expense recognized for service-based stock options was $0.2 million and $0.4 million for the three months ended March 31, 2022 and 2021, respectively. As of March 31, 2022, total stock-based compensation expense related to unvested options not yet recognized totaled approximately $1.0 million, which is expected to be recognized over an estimated weighted average remaining term of 3.1 years.

Licensing Agreements

Licensing Agreements	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Licensing Agreements	Licensing Agreements Product License Agreements The Company is a party to a Licensing Agreement between the Company and Charak, LLC ("Charak") dated January 7, 2002 (the "2002 Agreement") that grants the Company exclusive worldwide rights to certain patents and information related to our Triferic® product. On October 7, 2018, the Company entered into a Master Services and IP Agreement (the “Charak MSA”) with Charak and Dr. Ajay Gupta, a former Officer of the Company. Pursuant to the MSA, the parties entered into three additional agreements described below related to the license of certain soluble ferric pyrophosphate (“SFP”) intellectual property owned by Charak. As of March 31, 2022, the Company has accrued $86,400 relating to certain IP reimbursement expenses and certain sublicense royalty fees and is included within accrued liabilities on the condensed consolidated balance sheet. Pursuant to the Charak MSA, the aforementioned parties entered into an Amendment, dated as of October 7, 2018 (the “Charak Amendment”), to the 2002 Agreement, under which Charak granted the Company an exclusive, worldwide, non-transferable license to commercialize SFP for the treatment of patients with renal failure. The Charak Amendment amends the royalty payments due to Charak under the 2002 Agreement such that the Company is liable to pay Charak royalties on net sales by the Company of products developed under the license, which includes the Company’s Triferic® product, at a specified rate until December 31, 2021 and thereafter at a reduced rate from January 1, 2022 until February 1, 2034. Additionally, the Company shall pay Charak a percentage of any sublicense income during the term of the agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sublicensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and be no less than a lower rate of the net sales of the licensed products by the sublicensee in jurisdictions where there exists no valid claim, on a country-by-country basis. Also pursuant to the Charak MSA, the Company and Charak entered into a Commercialization and Technology License Agreement I.V. Triferic®, dated as of October 7, 2018 (the “IV Agreement”), under which Charak granted the Company an exclusive, sublicensable, royalty-bearing license to SFP for the purpose of commercializing certain intravenous-delivered products incorporating SFP for the treatment of iron disorders worldwide for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. The Company is liable to pay Charak royalties on net sales by the Company of products developed under the license at a specified rate until December 31, 2021. From January 1, 2022 until February 1, 2034, the Company is liable to pay Charak a base royalty at a reduced rate on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the IV Agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sublicensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sublicensee in jurisdictions where there exists no valid claim, on a country-by-country basis. Also pursuant to the Charak MSA, the Company and Charak entered into a Technology License Agreement TPN Triferic®, dated as of October 7, 2018 (the “TPN Agreement”), pursuant to which Charak granted the Company an exclusive, sublicensable, royalty-bearing license to SFP for the purpose of commercializing worldwide certain TPN products incorporating SFP. The license grant under the TPN Agreement continues for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. During the term of the TPN Agreement, the Company is liable to pay Charak a base royalty on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the TPN Agreement, which amount shall not be less than a minimum royalty on net sales of the licensed products by the sublicensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sublicensee in jurisdictions where there exists no valid claim, on a country-by-country basis. The potential milestone payments are not yet considered probable, and no milestone payments have been accrued at March 31, 2022.

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Leases	Leases Rockwell leases its production facilities and administrative offices as well as certain equipment used in its operations including leases on transportation equipment used in the delivery of its products. The lease terms range from monthly to seven years. Rockwell occupies a 51,000 square foot facility and a 17,500 square foot facility in Wixom, Michigan under a lease expiring in August 2024. Rockwell also occupies two other manufacturing facilities, a 51,000 square foot facility in Grapevine, Texas under a lease expiring in December 2025, and a 57,000 square foot facility in Greer, South Carolina under a lease expiring February 2023. In addition, Rockwell occupies 4,100 square feet of office space in Hackensack, New Jersey under a lease expiring on October 31, 2024. This lease was subleased on December 15, 2021 with an expiration date of October 31, 2024. At March 31, 2022, the Company had operating and finance lease liabilities of $7.4 million and right-of-use assets of $7.2 million, which are included in the consolidated balance sheet. At December 31, 2021, the Company had operating lease liabilities of $7.9 million and right-of-use assets of $7.7 million, which are included in the consolidated balance sheet. The following summarizes quantitative information about the Company’s operating leases (table in thousands): Three Months Ended March 31, 2022 Three Months Ended March 31, 2021 Operating leases Operating lease cost $ 449 $ 419 Variable lease cost 95 102 Operating lease expense 544 521 Finance leases Amortization of right-of-use assets 141 45 Interest on lease obligations 47 13 Finance lease expense 188 58 Short-term lease rent expense 4 4 Total rent expense $ 736 $ 583 Other information Operating cash flows from operating leases $ 464 $ 425 Operating cash flows from finance leases $ 47 $ 13 Financing cash flows from finance leases $ 118 $ 37 Right of use assets exchanged for operating lease liabilities $ — $ 1,896 Right of use assets exchanged for finance lease liabilities $ — $ 460 Weighted-average remaining lease term – operating leases 3.4 3.6 Weighted-average remaining lease term – finance leases 5.2 5.4 Weighted-average discount rate – operating leases 6.3 % 6.3 % Weighted-average discount rate – finance leases 6.4 % 5.4 % Future minimum rental payments under operating lease agreements are as follows (in thousands): Operating Finance Year ending December 31, 2022 (remaining) $ 1,307 $ 495 Year ending December 31, 2023 1,456 669 Year ending December 31, 2024 1,114 672 Year ending December 31, 2025 637 676 Year ending December 31, 2026 260 666 Remaining future payments 121 311 Total $ 4,895 $ 3,489 Less present value discount (485) (516) Operating and finance lease liabilities $ 4,410 $ 2,973
Leases	Leases Rockwell leases its production facilities and administrative offices as well as certain equipment used in its operations including leases on transportation equipment used in the delivery of its products. The lease terms range from monthly to seven years. Rockwell occupies a 51,000 square foot facility and a 17,500 square foot facility in Wixom, Michigan under a lease expiring in August 2024. Rockwell also occupies two other manufacturing facilities, a 51,000 square foot facility in Grapevine, Texas under a lease expiring in December 2025, and a 57,000 square foot facility in Greer, South Carolina under a lease expiring February 2023. In addition, Rockwell occupies 4,100 square feet of office space in Hackensack, New Jersey under a lease expiring on October 31, 2024. This lease was subleased on December 15, 2021 with an expiration date of October 31, 2024. At March 31, 2022, the Company had operating and finance lease liabilities of $7.4 million and right-of-use assets of $7.2 million, which are included in the consolidated balance sheet. At December 31, 2021, the Company had operating lease liabilities of $7.9 million and right-of-use assets of $7.7 million, which are included in the consolidated balance sheet. The following summarizes quantitative information about the Company’s operating leases (table in thousands): Three Months Ended March 31, 2022 Three Months Ended March 31, 2021 Operating leases Operating lease cost $ 449 $ 419 Variable lease cost 95 102 Operating lease expense 544 521 Finance leases Amortization of right-of-use assets 141 45 Interest on lease obligations 47 13 Finance lease expense 188 58 Short-term lease rent expense 4 4 Total rent expense $ 736 $ 583 Other information Operating cash flows from operating leases $ 464 $ 425 Operating cash flows from finance leases $ 47 $ 13 Financing cash flows from finance leases $ 118 $ 37 Right of use assets exchanged for operating lease liabilities $ — $ 1,896 Right of use assets exchanged for finance lease liabilities $ — $ 460 Weighted-average remaining lease term – operating leases 3.4 3.6 Weighted-average remaining lease term – finance leases 5.2 5.4 Weighted-average discount rate – operating leases 6.3 % 6.3 % Weighted-average discount rate – finance leases 6.4 % 5.4 % Future minimum rental payments under operating lease agreements are as follows (in thousands): Operating Finance Year ending December 31, 2022 (remaining) $ 1,307 $ 495 Year ending December 31, 2023 1,456 669 Year ending December 31, 2024 1,114 672 Year ending December 31, 2025 637 676 Year ending December 31, 2026 260 666 Remaining future payments 121 311 Total $ 4,895 $ 3,489 Less present value discount (485) (516) Operating and finance lease liabilities $ 4,410 $ 2,973

Loans and Security Agreement

Loans and Security Agreement	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Loans and Security Agreement	Loan and Security AgreementOn March 16, 2020, the Company and Rockwell Transportation, Inc., as Borrowers, entered into a Loan and Security Agreement (the "Loan Agreement") with Innovatus Life Sciences Lending Fund I, LP ("Innovatus"), as collateral agent and the lenders party thereto, pursuant to which Innovatus, as a lender, agreed to make certain term loans to the Company in the aggregate principal amount of up to $35.0 million (the "Term Loans"). Funding of the first $22.5 million tranche was completed on March 16, 2020. The Company is no longer eligible to draw on a second tranche of $5.0 million, which was tied to the achievement of certain milestones by a specific date. The Company may be eligible to draw on a third tranche of $7.5 million upon the achievement of certain additional milestones, including the achievement of certain Triferic sales thresholds. Net draw down proceeds were $21.2 million with closing costs of $1.3 million. In connection with each funding of the Term Loans, the Company is required to issue to Innovatus a warrant (the “Warrants”) to purchase a number of shares of the Company’s common stock equal to 3.5% of the principal amount of the relevant Term Loan funded divided by the exercise price, which will be based on the lower of (i) the volume weighted average closing price of the Company’s stock for the 5-trading day period ending on the last trading day immediately preceding the execution of the Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the Loan Agreement (or for the second and third tranches only at the lower of (i) $18.15 per share or (ii) the volume weighted average closing price of the Company’s stock for the 5-trading day period ending on the last trading day immediately preceding the relevant Term Loan funding). The Warrants may be exercised on a cashless basis and are immediately exercisable through the seventh anniversary of the applicable funding date. The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in such Warrant. In connection with the first tranche of the Term Loans, the Company issued a Warrant to Innovatus, exercisable for an aggregate of 43,388 shares of the Company’s common stock at an exercise price of $18.15 per share. The Company evaluated the warrant under ASC 470, Debt, and recognized an additional debt discount of approximately $0.5 million based on the relative fair value of the base instruments and warrants. The Company calculated the fair value of the warrant using the Black-Scholes model. The Company is entitled to make interest-only payments for thirty months, or up to thirty-six months if certain conditions are met. The Term Loans will mature on March 16, 2025, and will bear interest at the greater of (i) Prime Rate (as defined in the Loan Agreement) and (ii) 4.75%, plus 4.00% with an initial interest rate of 8.75% per annum and an effective interest rate of 10.9%. The Company has the option, under certain circumstances, to add 1.00% of such interest rate amount to the then outstanding principal balance in lieu of paying such amount in cash. For the three months ended March 31, 2022 and 2021, interest expense amounted to $0.4 million and $0.6 million, respectively. The Loan Agreement is secured by all assets of the Company and Rockwell Transportation, Inc. Proceeds are used for working capital purposes. The Loan Agreement contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and trailing twelve months sales of Triferic, with the latter beginning with the period ending December 31, 2020. The Company cannot assure you that we can maintain compliance with the covenants under our Loan Agreement, which may result in an event of default. The Company's ability to comply with these covenants may be adversely affected by events beyond its control. For example, the Loan Agreement contains certain financial covenants relating to sales and, as a result of the ongoing COVID-19 pandemic and its effect on the Company's sales activities, among other factors, the Company may not be able to satisfy such covenants in the future. If the Company is unable to comply with the covenants under the Loan Agreement, it would pursue all available cure options in order to regain compliance. However, the Company may not be able to mutually agree with Innovatus on appropriate remedies to cure a future breach of a covenant, which could give rise to an event of default. If the Company is unable to avoid an event of default, any required repayments could have an adverse effect on its liquidity. In September 2021, the Company entered into an amendment to the Loan Agreement in which the Company, in exchange for Innovatus lowering the sales covenants, agreed to (i) prepay an aggregate principal amount of $7,500,000 in ten installments commencing on December 1, 2021; (ii) pay an additional prepayment premium of 5% on prepaid amounts if the Company elects to prepay all outstanding Term Loans on or before September 24, 2023 and (iii) maintain minimum liquidity of no less than $5,000,000 if the aggregate principal amount of Term Loans is greater than $15,000,000 pursuant to the liquidity covenant in the Loan Agreement. On March 31, 2022, the Collateral Agent and Lenders consented to the delivery to Collateral Agent and Lenders of its annual audited financial statements for the fiscal year 2021 by April 15, 2022 as opposed to within 90 days of December 31, 2021, as required pursuant to Loan Agreement. As of March 31, 2022, the Company was in compliance with all covenants under the Loan Agreement. As of March 31, 2022, the outstanding balance of the Term Loan was $18.4 million, net of unamortized issuance costs and discount of $1.1 million. The following table reflects the schedule of principal payments on the Term Loan as of March 31, 2022 (in thousands): Principal Payments 2022 $ 5,500 2023 6,000 2024 6,000 2025 2,000 $ 19,500

Insurance Financing Note Payabl

Insurance Financing Note Payable	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Insurance Financing Note Payable	Insurance Financing Note PayableOn July 3, 2021, the Company entered into a short-term note payable for $2.0 million, bearing interest at 3.93% per annum to finance various insurance policies. Principal and interest payments related to this note began on July 3, 2021 and were paid on a straight-line amortization over 9 months with the final payment due on March 3, 2022. As of March 31, 2022, the Company's insurance note payable was paid in full.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Amended Supply Agreement The Company has been working to renegotiate certain terms of its supply contracts with the Company’s two largest customers in an effort to allow the Company to stabilize its concentrates business. On April 6, 2022, the Company and DaVita entered into an amendment (the "Amendment") to the Products Purchase Agreement, dated July 1, 2019 under which the Company supplies DaVita with certain dialysis concentrates. Under the Amendment, the Company and DaVita agreed to a price increase, effective May 1, 2022, as well as the pass-through of certain inflationary costs, determined on a quarterly basis. Certain costs are subject to a cap. The Amendment also requires the Company to implement certain cost containment and cost-cutting measures. The Amendment contains certain covenants with respect to the Company’s ongoing operations, including a minimum cash covenant, and the requirement to raise $15 million in additional capital by June 30, 2022. The Amendment also establishes a joint committee that will oversee certain efficiency and cost-savings activities to be undertaken by the Company. Certain cost savings that are realized by the Company will be shared with DaVita in the manner set forth in the Amendment. Controlled Equity Offering (or "At the Market" Offering) On April 8, 2022, the Company entered into a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may offer and sell from time to time up to $12,200,000 of shares of Company’s common stock through the Agent. The offering and sale of such shares has been registered under the Securities Act of 1933, as amended, pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-259923) (the “Registration Statement”), which was originally filed with the SEC on September 30, 2021 and declared effective by the SEC on October 8, 2021, the base prospectus contained within the Registration Statement, and a prospectus supplement that was filed with the SEC on April 8, 2022. Reverse Stock Split On May 9, 2022, the Company's Board of Directors approved the reverse stock split at the ratio of 1-for-11 shares. The reverse stock split was approved by the Company's stockholders at the annual meeting of stockholders held on May 9, 2022 at a ratio ranging from 1-for-2 up to a ratio of 1-for-15, such ratio to be determined by the Board of Directors and included in a public announcement. The reverse stock split will became effective at 12:01 a.m. Eastern Time on May 13, 2022. Rockwell Medical's common stock is expected to begin trading on the Nasdaq Capital Market on a split-adjusted basis on May 13, 2022.

Basis of Presentation, Summar_2

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.
Reverse Stock Split	Reverse Stock Split On May 9, 2022, the stockholders of the Company authorized our Board of Directors to effect a reverse stock split of all outstanding shares of common stock. The Board of Directors subsequently approved the implementation of a reverse stock split as a ratio of one-for-eleven shares, which became effective on May 13, 2022. The Company’s outstanding stock options were also adjusted to reflect the one-for-eleven reverse stock split of the Company’s common stock. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The reverse stock split resulted in an adjustment to the Series X convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. All share and per share data in these condensed consolidated financial statements and related notes hereto have been retroactively adjusted to the account for the effect of the reverse stock split for the three month periods ended March 31, 2022 and 2021, respectively, and the balance sheet at March 31, 2022 and December 31, 2021.
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Leases	Leases The Company accounts for its leases under Accounting Standards Codification (“ASC”) 842, Leases . Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred. In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.
Loss Per Share	Loss Per Share ASC 260, Earnings Per Share , requires dual presentation of basic and diluted earnings per share (“EPS”), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity.
Adoption of Recent Accounting Pronouncements	Adoption of Recent Accounting Pronouncements The Company continually assesses new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures that there are sufficient controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change.

Basis of Presentation, Summar_3

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Potentially Dilutive Securities	Securities that could potentially dilute net income per share in the future that were not included in the computation of diluted loss per share were as follows: As of March 31, 2022 2021 Options to purchase common stock 511,117 558,417 Unvested restricted stock awards 891 7,118 Unvested restricted stock units 28,067 21,611 Warrants to purchase common stock 2,402,442 2,402,442 Total 2,942,517 2,989,588

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. In thousands of U.S. dollars ($) Three Months Ended March 31, 2022 Products By Geographic Area Total U.S. Rest of World Drug Revenues Product Sales – Point-in-time $ 159 $ 159 $ — License Fee – Over time 62 — 62 Total Drug Products 221 159 62 Concentrate Products Product Sales – Point-in-time 15,427 13,810 1,617 License Fee – Over time 476 476 — Total Concentrate Products 15,903 14,286 1,617 Net Revenue $ 16,124 $ 14,445 $ 1,679 In thousands of U.S. dollars ($) Three Months Ended March 31, 2021 Products By Geographic Area Total U.S. Rest of World Drug Revenues Product Sales – Point-in-time $ 225 $ 225 $ — License Fee – Over time 58 — 58 Total Drug Products 283 225 58 Concentrate Products Product Sales – Point-in-time 14,705 13,201 1,504 License Fee – Over time 485 485 — Total Concentrate Products 15,190 13,686 1,504 Net Revenue $ 15,473 $ 13,911 $ 1,562
Contract Balances	The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers. In thousands of U.S. dollars ($) March 31, 2022 December 31, 2021 Receivables, which are included in "Trade and other receivables" $ 7,121 $ 5,913 Contract liabilities $ 7,619 $ 8,157

Investments - Available-for-S_2

Investments - Available-for-Sale (Tables)	3 Months Ended
	Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Investments Available-for-Sale	Investments available-for-sale consisted of the following as of December 31, 2021 (table in thousands): December 31, 2021 Amortized Cost Unrealized Gain Unrealized Loss Accrued Interest Fair Value Available-for-Sale Securities Bonds $ 9,143 $ 1 $ — $ 14 $ 9,158

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Schedule Components of Inventory	Components of inventory, net of reserves, as of March 31, 2022 and December 31, 2021 are as follows (table in thousands): March 31, December 31, Raw Materials $ 4,312 $ 3,434 Work in Process 408 201 Finished Goods 2,334 1,964 Total $ 7,054 $ 5,599

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Major Classes of Property and Equipment	As of March 31, 2022 and December 31, 2021, the Company’s property and equipment consisted of the following (table in thousands): March 31, December 31, Leasehold Improvements $ 1,204 $ 1,204 Machinery and Equipment 5,867 5,864 Information Technology & Office Equipment 1,845 1,845 Laboratory Equipment 660 676 9,576 9,589 Accumulated Depreciation (7,199) (7,103) Property and Equipment, net $ 2,377 $ 2,486

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities as of March 31, 2022 and December 31, 2021 consisted of the following (table in thousands): March 31, December 31, Accrued Research & Development Expense $ 338 $ 366 Accrued Compensation and Benefits 1,158 1,791 Accrued Unvouchered Receipts 537 796 Accrued Workers Compensation 458 382 Other Accrued Liabilities 1,882 1,755 Total Accrued Liabilities $ 4,373 $ 5,090

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Schedule of Total Stock-Based Compensation Expense	The Company recognized total stock-based compensation expense during the three months ended March 31, 2022 and 2021 as follows (table in thousands): Three Months Ended 2022 2021 Service-based awards: Restricted stock units $ 12 $ 104 Stock option awards 200 391 212 495 Performance-based awards: Restricted stock awards (391) (391) Stock option awards — (340) (391) (731) Total $ (179) $ (236)
Restricted stock awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Schedule of Restricted Stock Awards	A summary of the Company’s restricted stock awards during the three months ended March 31, 2022 is as follows: Number of Shares Weighted Average Unvested at January 1, 2022 7,118 $ 62.70 Forfeited (6,227) $ 62.70 Unvested at March 31, 2022 891 $ 62.70 A summary of the Company’s restricted stock awards during the three months ended March 31, 2021 is as follows: Number of Shares Weighted Average Unvested at January 1, 2021 13,345 $ 62.70 Forfeited (6,227) $ 62.70 Unvested at March 31, 2021 7,118 $ 62.70
Restricted stock units - service based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Schedule of Restricted Stock Awards	A summary of the Company’s service-based restricted stock units during the three months ended March 31, 2022 is as follows: Number of Shares Weighted Average Unvested at January 1, 2022 29,289 $ 12.87 Forfeited (1,223) 52.91 Unvested at March 31, 2022 28,066 $ 11.11 A summary of the Company’s service-based restricted stock units during the three months ended March 31, 2021 is as follows: Number of Shares Weighted Average Unvested at January 1, 2021 24,136 $ 28.60 Granted 914 22.99 Vested (1,042) 52.91 Forfeited (2,396) 27.50 Unvested at March 31, 2021 21,612 $ 27.39
Stock option awards - service based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Schedule of Stock Option Assumptions	The fair value of the service-based stock options granted for the three months ended March 31, 2022 were based on the following assumptions: March 31, Exercise price $4.12 Expected stock price volatility 76.2% Risk-free interest rate 1.98% Term (years) 6.5
Schedule of Stock Options Activity	A summary of the Company’s service-based stock option activity for the three months ended March 31, 2022 is as follows: Shares Weighted Weighted Aggregate Outstanding at January 1, 2022 528,591 $ 32.01 7.5 $ — Granted 909 4.07 9.9 — Forfeited (14,839) 17.49 — — Expired (3,545) 85.36 — — Outstanding at March 31, 2022 511,116 $ 32.01 7.0 $ 1 Exercisable at March 31, 2022 236,720 $ 52.14 5.0 $ — A summary of the Company’s service-based stock option activity for the three months ended March 31, 2021 is as follows: Shares Weighted Weighted Aggregate Outstanding at January 1, 2021 519,814 $ 50.05 6.6 $ — Granted 7,672 17.60 6.0 — Forfeited (16,721) 27.39 — — Expired (20,530) 84.26 — — Outstanding at March 31, 2021 490,235 $ 48.95 6.1 $ — Exercisable at March 31, 2021 251,180 $ 73.48 3.2 $ —

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Summary of Lease Costs	The following summarizes quantitative information about the Company’s operating leases (table in thousands): Three Months Ended March 31, 2022 Three Months Ended March 31, 2021 Operating leases Operating lease cost $ 449 $ 419 Variable lease cost 95 102 Operating lease expense 544 521 Finance leases Amortization of right-of-use assets 141 45 Interest on lease obligations 47 13 Finance lease expense 188 58 Short-term lease rent expense 4 4 Total rent expense $ 736 $ 583 Other information Operating cash flows from operating leases $ 464 $ 425 Operating cash flows from finance leases $ 47 $ 13 Financing cash flows from finance leases $ 118 $ 37 Right of use assets exchanged for operating lease liabilities $ — $ 1,896 Right of use assets exchanged for finance lease liabilities $ — $ 460 Weighted-average remaining lease term – operating leases 3.4 3.6 Weighted-average remaining lease term – finance leases 5.2 5.4 Weighted-average discount rate – operating leases 6.3 % 6.3 % Weighted-average discount rate – finance leases 6.4 % 5.4 %
Operating Lease Maturities	Future minimum rental payments under operating lease agreements are as follows (in thousands): Operating Finance Year ending December 31, 2022 (remaining) $ 1,307 $ 495 Year ending December 31, 2023 1,456 669 Year ending December 31, 2024 1,114 672 Year ending December 31, 2025 637 676 Year ending December 31, 2026 260 666 Remaining future payments 121 311 Total $ 4,895 $ 3,489 Less present value discount (485) (516) Operating and finance lease liabilities $ 4,410 $ 2,973
Finance Lease Maturities	Future minimum rental payments under operating lease agreements are as follows (in thousands): Operating Finance Year ending December 31, 2022 (remaining) $ 1,307 $ 495 Year ending December 31, 2023 1,456 669 Year ending December 31, 2024 1,114 672 Year ending December 31, 2025 637 676 Year ending December 31, 2026 260 666 Remaining future payments 121 311 Total $ 4,895 $ 3,489 Less present value discount (485) (516) Operating and finance lease liabilities $ 4,410 $ 2,973

Loans and Security Agreement (T

Loans and Security Agreement (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Schedule of Principal Payments on Term Loan	The following table reflects the schedule of principal payments on the Term Loan as of March 31, 2022 (in thousands): Principal Payments 2022 $ 5,500 2023 6,000 2024 6,000 2025 2,000 $ 19,500

Description of Business (Detail

Description of Business (Details) $ in Millions	3 Months Ended
	Mar. 31, 2022USD ($)employee
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Years of service	25 years
Revenue | $	$ 60
Number of employees | employee	300

Liquidity and Going Concern C_2

Liquidity and Going Concern Considerations (Details)	Apr. 08, 2022USD ($)	Apr. 07, 2022USD ($)	Jun. 30, 2022USD ($)	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)	Dec. 08, 2021businessDay$ / shares	Apr. 06, 2022USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Liquidity and Going Concern Considerations [Line Items]
Accumulated deficit				$ (377,242,000)				$ (370,080,000)
Stockholders' equity				(4,807,000)	$ 26,178,000			2,535,000	$ 34,170,000
Cash and Cash Equivalents				9,914,000				$ 13,280,000
Working capital				5,200,000
Net cash used in operating activities				$ (9,812,000)	$ (12,495,000)
Period to regain Nasdaq minimum bid requirements						180 days
Common stock, closing bid price (at least) (in dollars per share) | $ / shares						$ 1
Number of consecutive business days (minimum) | businessDay						10
Subsequent event
Liquidity and Going Concern Considerations [Line Items]
Additional capital earned			$ 15,000,000				$ 15,000,000
Subsequent event | Da Vita Healthcare Partners Inc | Share Issuance, Tranche One
Liquidity and Going Concern Considerations [Line Items]
Proceeds from issuance of convertible preferred stock		$ 7,500,000
Subsequent event | Da Vita Healthcare Partners Inc | Forecast | Share Issuance, Tranche One
Liquidity and Going Concern Considerations [Line Items]
Proceeds from issuance of convertible preferred stock		$ 7,500,000
Subsequent event | Da Vita Healthcare Partners Inc | Forecast | Share Issuance, Tranche Two
Liquidity and Going Concern Considerations [Line Items]
Proceeds from issuance of convertible preferred stock			7,500,000
Subsequent event | Da Vita Healthcare Partners Inc | Forecast | Series X Convertible Preferred Stock | Private Placement
Liquidity and Going Concern Considerations [Line Items]
Sale of stock, consideration received on transaction			$ 15,000,000
Subsequent event | Cantor Fitzgerald & Co
Liquidity and Going Concern Considerations [Line Items]
Sales agreement, threshold sale of shares	$ 12,200,000

Basis of Presentation, Summar_4

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Summary of Potentially Dilutive Securities (Details)	May 09, 2022	Mar. 31, 2022shares	Mar. 31, 2021shares
Net Earnings per Share
Securities excluded from diluted loss per share calculation (in shares)		2,942,517	2,989,588
Subsequent event
Net Earnings per Share
Reverse stock split	0.09
Options to purchase common stock
Net Earnings per Share
Securities excluded from diluted loss per share calculation (in shares)		511,117	558,417
Unvested restricted stock awards
Net Earnings per Share
Securities excluded from diluted loss per share calculation (in shares)		891	7,118
Unvested restricted stock units
Net Earnings per Share
Securities excluded from diluted loss per share calculation (in shares)		28,067	21,611
Warrants to purchase common stock
Net Earnings per Share
Securities excluded from diluted loss per share calculation (in shares)		2,402,442	2,402,442

Revenue Recognition - Nature of

Revenue Recognition - Nature of Goods and Services (Details)	3 Months Ended
	Mar. 31, 2022agreement
Revenue from Contract with Customer [Abstract]
Number of distribution and license agreements	5
Customers average payment term	30 days
Distributors average payment term	45 days

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Net Revenue	$ 16,124	$ 15,473
Drug products
Disaggregation of Revenue [Line Items]
Net Revenue	221	283
Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	15,903	15,190
U.S.
Disaggregation of Revenue [Line Items]
Net Revenue	14,445	13,911
U.S. | Drug products
Disaggregation of Revenue [Line Items]
Net Revenue	159	225
U.S. | Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	14,286	13,686
Rest of World
Disaggregation of Revenue [Line Items]
Net Revenue	1,679	1,562
Rest of World | Drug products
Disaggregation of Revenue [Line Items]
Net Revenue	62	58
Rest of World | Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	1,617	1,504
Product Sales – Point-in-time | Drug product sales
Disaggregation of Revenue [Line Items]
Net Revenue	159	225
Product Sales – Point-in-time | Concentrate product sales
Disaggregation of Revenue [Line Items]
Net Revenue	15,427	14,705
Product Sales – Point-in-time | U.S. | Drug product sales
Disaggregation of Revenue [Line Items]
Net Revenue	159	225
Product Sales – Point-in-time | U.S. | Concentrate product sales
Disaggregation of Revenue [Line Items]
Net Revenue	13,810	13,201
Product Sales – Point-in-time | Rest of World | Drug product sales
Disaggregation of Revenue [Line Items]
Net Revenue	0	0
Product Sales – Point-in-time | Rest of World | Concentrate product sales
Disaggregation of Revenue [Line Items]
Net Revenue	1,617	1,504
License Fee – Over time | Drug license fee
Disaggregation of Revenue [Line Items]
Net Revenue	62	58
License Fee – Over time | Concentrate product license fee
Disaggregation of Revenue [Line Items]
Net Revenue	476	485
License Fee – Over time | U.S. | Drug license fee
Disaggregation of Revenue [Line Items]
Net Revenue	0	0
License Fee – Over time | U.S. | Concentrate product license fee
Disaggregation of Revenue [Line Items]
Net Revenue	476	485
License Fee – Over time | Rest of World | Drug license fee
Disaggregation of Revenue [Line Items]
Net Revenue	62	58
License Fee – Over time | Rest of World | Concentrate product license fee
Disaggregation of Revenue [Line Items]
Net Revenue	$ 0	$ 0

Revenue Recognition - Contract

Revenue Recognition - Contract Balances (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Receivables, which are included in "Trade and other receivables"	$ 7,121	$ 5,913
Contract liabilities	$ 7,619	$ 8,157

Revenue Recognition - Narrative

Revenue Recognition - Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Revenue Recognition [Line Items]
Impairment losses	$ 0	$ 0
Contract assets	0		$ 0
Revenue performance obligation	7,600,000
Baxter Healthcare Organization
Revenue Recognition [Line Items]
Revenue performance obligation	4,800,000
Concentrate Products
Revenue Recognition [Line Items]
Reserve for returns	$ 0		$ 0

Investments - Available-for-S_3

Investments - Available-for-Sale (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Amortized Cost		$ 9,143
Unrealized Gain		1
Unrealized Loss		0
Accrued Interest		14
Fair Value	$ 0	$ 9,158

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Inventory [Line Items]
Raw Materials	$ 4,312	$ 3,434
Work in Process	408	201
Finished Goods	2,334	1,964
Total	7,054	5,599
Inventory, noncurrent	1,523	1,523
Inventory, net	5,531	$ 4,076
Triferic Inventory
Inventory [Line Items]
Raw Materials	900
Inventory, noncurrent	1,500
Inventory, net	$ 1,600
Useful life	25 years
Triferic Dialysate
Inventory [Line Items]
Finished Goods	$ 300
Triferic API
Inventory [Line Items]
Inventory, net	$ 400

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Property and equipment
Gross property and equipment	$ 9,576		$ 9,589
Accumulated Depreciation	(7,199)		(7,103)
Property and Equipment, net	2,377		2,486
Depreciation expense	100	$ 200
Leasehold Improvements
Property and equipment
Gross property and equipment	1,204		1,204
Machinery and Equipment
Property and equipment
Gross property and equipment	5,867		5,864
Information Technology & Office Equipment
Property and equipment
Gross property and equipment	1,845		1,845
Laboratory Equipment
Property and equipment
Gross property and equipment	$ 660		$ 676

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued Research & Development Expense	$ 338	$ 366
Accrued Compensation and Benefits	1,158	1,791
Accrued Unvouchered Receipts	537	796
Accrued Workers Compensation	458	382
Other Accrued Liabilities	1,882	1,755
Total Accrued Liabilities	$ 4,373	$ 5,090

Deferred Revenue (Details)

Deferred Revenue (Details) - USD ($)	1 Months Ended				3 Months Ended		12 Months Ended
	Jun. 30, 2021	Sep. 30, 2020	Jan. 31, 2020	Oct. 31, 2014	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2016	Dec. 31, 2021
Deferred Revenue Arrangement [Line Items]
Deferred revenue					$ 7,619,000			$ 8,157,000
Baxter Healthcare Organization
Deferred Revenue Arrangement [Line Items]
Term of agreement				10 years
Upfront payment				$ 20,000,000
Recognized deferred revenue					500,000	$ 500,000
Deferred revenue					4,800,000			5,200,000
Wanbang Biopharmaceutical
Deferred Revenue Arrangement [Line Items]
Upfront payment							$ 4,000,000
Recognized deferred revenue					100,000
Deferred revenue					2,500,000			2,500,000
Sun Pharma Agreements
Deferred Revenue Arrangement [Line Items]
Upfront payment			$ 100,000
Recognized deferred revenue					2,500	2,500
Deferred revenue					77,500			80,000
Jeil Pharma Agreements
Deferred Revenue Arrangement [Line Items]
Upfront payment		$ 200,000
Recognized deferred revenue					2,500	2,500
Deferred revenue					200,000			200,000
Drogsan Agreements
Deferred Revenue Arrangement [Line Items]
Upfront payment	$ 150,000
Recognized deferred revenue					3,750	$ 0
Deferred revenue					$ 140,000			$ 140,000

Stockholders_ Equity (Details)

Stockholders’ Equity (Details)	Apr. 07, 2022USD ($)shares	Apr. 06, 2022USD ($)$ / shares	Jun. 30, 2022USD ($)shares	Mar. 31, 2022$ / sharesshares	Dec. 31, 2021$ / sharesshares
Class of Stock [Line Items]
Preferred stock, authorized (in shares)				2,000,000	2,000,000
Preferred shares, par value (in dollars per share) | $ / shares				$ 0.0001	$ 0.0001
Preferred shares, shares issued (in shares)				0	0
Preferred shares, shares outstanding (in shares)				0	0
Common shares, shares authorized (in shares)				170,000,000	170,000,000
Common shares, par value (in dollars per share) | $ / shares				$ 0.0001	$ 0.0001
Common shares, shares issued (in shares)				8,544,225	8,544,225
Common shares, shares outstanding (in shares)				8,544,225	8,544,225
Subsequent event
Class of Stock [Line Items]
Additional capital earned | $		$ 15,000,000	$ 15,000,000
Series X Convertible Preferred Stock | Subsequent event
Class of Stock [Line Items]
Interest rate percentage		100.00%
Common stock trading price | $ / shares		$ 22
Common stock trading period		30 years
Conversion price (per share) | $ / shares		$ 11
Convertible preferred stock (in shares)		91
Outstanding common stock, percentage		9.90%
Outstanding common stock, not to exceed, percentage		19.90%
Percentage of investment owned		50.00%
Maximum working capital line | $		$ 5,000,000
Da Vita Healthcare Partners Inc | Subsequent event | Share Issuance, Tranche One
Class of Stock [Line Items]
Proceeds from issuance of convertible preferred stock | $	$ 7,500,000
Da Vita Healthcare Partners Inc | Forecast | Subsequent event | Share Issuance, Tranche One
Class of Stock [Line Items]
Proceeds from issuance of convertible preferred stock | $	$ 7,500,000
Da Vita Healthcare Partners Inc | Forecast | Subsequent event | Share Issuance, Tranche Two
Class of Stock [Line Items]
Proceeds from issuance of convertible preferred stock | $			7,500,000
Private Placement | Da Vita Healthcare Partners Inc | Series X Convertible Preferred Stock | Subsequent event
Class of Stock [Line Items]
Common stock trading price (in dollars per share) | $ / shares		$ 1,000
Private Placement | Da Vita Healthcare Partners Inc | Series X Convertible Preferred Stock | Subsequent event | Share Issuance, Tranche One
Class of Stock [Line Items]
Sale of Stock, number of shares issued in transaction	7,500
Private Placement | Da Vita Healthcare Partners Inc | Forecast | Series X Convertible Preferred Stock | Subsequent event
Class of Stock [Line Items]
Sale of stock, consideration received on transaction | $			$ 15,000,000
Private Placement | Da Vita Healthcare Partners Inc | Forecast | Series X Convertible Preferred Stock | Subsequent event | Share Issuance, Tranche Two
Class of Stock [Line Items]
Sale of Stock, number of shares issued in transaction			7,500

Stock-Based Compensation - Shar

Stock-Based Compensation - Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	$ (179)	$ (236)
Service based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	212	495
Restricted stock units - service based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	12	104
Stock option awards - service based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	200	391
Performance based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	(391)	(731)
Restricted stock awards - performance based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	(391)	(391)
Stock option awards - performance based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	$ 0	$ (340)

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Awards (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Weighted Average Grant-Date Fair Value
Stock based compensation expenses	$ (179)	$ (236)
Restricted stock awards
Number of Shares
Unvested at beginning of period (in shares)	7,118	13,345
Forfeited (in shares)	(6,227)	(6,227)
Unvested at end of period (in shares)	891	7,118
Weighted Average Grant-Date Fair Value
Unvested at beginning of period (in dollars per share)	$ 62.70	$ 62.70
Forfeited (in dollars per share)	62.70	62.70
Unvested at end of period (in dollars per share)	$ 62.70	$ 62.70
Vesting period	20 months
Unvested, number of shares (in shares)	891	7,118
Forfeited (in shares)	(6,227)	(6,227)
Restricted stock awards - performance based awards
Number of Shares
Forfeited (in shares)	(6,227)
Weighted Average Grant-Date Fair Value
Forfeited (in shares)	(6,227)
Stock based compensation expenses	$ (391)	$ (391)

Stock-Based Compensation - Serv

Stock-Based Compensation - Service Based Restricted Stock Units (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Weighted Average Grant-Date Fair Value
Stock based compensation expenses	$ (179)	$ (236)
Restricted stock units - service based awards
Number of Shares
Unvested at beginning of period (in shares)	29,289	24,136
Granted (in shares)		914
Vested (in shares)		(1,042)
Forfeited (in shares)	(1,223)	(2,396)
Unvested at end of period (in shares)	28,066	21,612
Weighted Average Grant-Date Fair Value
Unvested at beginning of period (in dollars per share)	$ 12.87	$ 28.60
Granted (in dollars per share)		22.99
Vested (in dollars per share)		52.91
Forfeited (in dollars per share)	52.91	27.50
Unvested at end of period (in dollars per share)	$ 11.11	$ 27.39
Stock based compensation expenses	$ 12	$ 104
Unrecognized stock-based compensation expense	$ 100
Unrecognized stock-based compensation expense, weighted average remaining term (in years) (less than)	1 year
Restricted stock units - service based awards | Minimum
Weighted Average Grant-Date Fair Value
Vesting period	1 year
Restricted stock units - service based awards | Maximum
Weighted Average Grant-Date Fair Value
Vesting period	3 years

Stock-Based Compensation - Se_2

Stock-Based Compensation - Service Based Stock Options - Fair Value Assumptions (Details) - Stock option awards - service based awards	3 Months Ended
	Mar. 31, 2022$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price (in dollars per share)	$ 4.12
Expected stock price volatility	76.20%
Risk-free interest rate	1.98%
Term (years)	6 years 6 months

Stock-Based Compensation - Se_3

Stock-Based Compensation - Service Based Stock Options (Details) - Stock option awards - service based awards - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2021	Dec. 31, 2020
Shares Underlying Options
Outstanding at the beginning of the period (in shares)	528,591	519,814	519,814
Granted (in shares)	909	7,672
Forfeited (in shares)	(14,839)	(16,721)
Expired (in shares)	(3,545)	(20,530)
Outstanding at the end of the period (in shares)	511,116	490,235
Exercisable at end of period (in shares)	236,720	251,180
Weighted Average Exercise Price
Outstanding at the beginning of the period (in dollars per share)	$ 32.01	$ 50.05	$ 50.05
Granted (in dollars per share)	4.07	17.60
Forfeited (in dollars per share)	17.49	27.39
Expired (in dollar per share)	85.36	84.26
Outstanding at the end of the period (in dollars per share)	32.01	48.95
Exercisable at end of the period (in dollars per share)	$ 52.14	$ 73.48
Weighted Average Remaining Contractual Term
Outstanding	7 years	6 years 1 month 6 days	7 years 6 months	6 years 7 months 6 days
Granted	9 years 10 months 24 days	6 years
Exercisable at end of the period	5 years	3 years 2 months 12 days
Aggregate Intrinsic Value
Outstanding	$ 1	$ 0			$ 0	$ 0
Exercisable at end of the period	$ 0	$ 0

Stock-Based Compensation - Se_4

Stock-Based Compensation - Service Based Stock Options - Others (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expenses	$ (179)	$ (236)
Stock option awards - service based awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	909	7,672
Forfeited (in shares)	14,839	16,721
Expirations (in shares)	3,545	20,530
Stock based compensation expenses	$ 200	$ 391
Unrecognized stock-based compensation expenses	$ 1,000
Unrecognized stock-based compensation expense, weighted average remaining term (in years)	3 years 1 month 6 days

Licensing Agreements (Details)

Licensing Agreements (Details)	Oct. 07, 2018agreement	Mar. 31, 2022USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of additional agreements | agreement	3
Master Services And Ip Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, accrued reimbursement of IP expenses and sublicense royalty fees		$ 86,400
Milestone payments		$ 0

Leases - Narrative (Details)

Leases - Narrative (Details) $ in Thousands	Mar. 31, 2022USD ($)ft²	Dec. 31, 2021USD ($)
Lessee, Lease, Description [Line Items]
Operating lease and finance lease liabilities | $	$ 7,400
Operating lease and finance lease, right of use assets, net | $	7,200	$ 7,737
Operating lease liabilities | $	$ 4,410	7,900
Operating lease, right of use assets | $		$ 7,700
Wixom, Michigan | Wixom, Michigan Property One
Lessee, Lease, Description [Line Items]
Facility sqft.	51,000
Wixom, Michigan | Wixom, Michigan Property Two
Lessee, Lease, Description [Line Items]
Facility sqft.	17,500
Grapevine, Texas
Lessee, Lease, Description [Line Items]
Facility sqft.	51,000
Greer, South Carolina
Lessee, Lease, Description [Line Items]
Facility sqft.	57,000
Hackensack, New Jersey
Lessee, Lease, Description [Line Items]
Facility sqft.	4,100
Maximum
Lessee, Lease, Description [Line Items]
Lease term	7 years

Leases - Summary of Lease Costs

Leases - Summary of Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating leases
Operating lease cost	$ 449	$ 419
Variable lease cost	95	102
Operating lease expense	544	521
Finance leases
Amortization of right-of-use assets	141	45
Interest on lease obligations	47	13
Finance lease expense	188	58
Short-term lease rent expense	4	4
Total rent expense	736	583
Other information
Operating cash flows from operating leases	464	425
Operating cash flows from finance leases	47	13
Financing cash flows from finance leases	118	37
Right of use assets exchanged for operating lease liabilities	0	1,896
Right of use assets exchanged for finance lease liabilities	$ 0	$ 460
Weighted-average remaining lease term – operating leases	3 years 4 months 24 days	3 years 7 months 6 days
Weighted-average remaining lease term – finance leases	5 years 2 months 12 days	5 years 4 months 24 days
Weighted-average discount rate – operating leases	6.30%	6.30%
Weighted-average discount rate – finance leases	6.40%	5.40%

Leases - Finance Lease and Oper

Leases - Finance Lease and Operating Lease Maturities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Operating
Year ending December 31, 2022 (remaining)	$ 1,307
Year ending December 31, 2023	1,456
Year ending December 31, 2024	1,114
Year ending December 31, 2025	637
Year ending December 31, 2026	260
Remaining future payments	121
Total	4,895
Less present value discount	(485)
Operating lease liabilities	4,410	$ 7,900
Finance
Year ending December 31, 2022 (remaining)	495
Year ending December 31, 2023	669
Year ending December 31, 2024	672
Year ending December 31, 2025	676
Year ending December 31, 2026	666
Remaining future payments	311
Total	3,489
Less present value discount	(516)
Finance lease liabilities	$ 2,973

Loans and Security Agreement -

Loans and Security Agreement - Narrative (Details) - Term loan	Sep. 24, 2021USD ($)installment	Mar. 16, 2020USD ($)$ / sharesshares	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)
Term loan
Debt Instrument [Line Items]
Aggregate principal amount	$ 7,500,000				$ 35,000,000
Calculation for number of shares of common stock able to be purchased by warrant, percentage of principal amount of relevant term loan funded funded		3.50%
Warrant exercise price calculation, period immediately preceding execution of loan agreement, number of trading days		5 days
Interest rate, base percentage		4.75%
Interest rate, additional percentage added to base percentage		4.00%
Initial interest rate percentage		8.75%
Effective interest rate		10.90%
Option to add interest rate amount to outstanding principal balance in lieu of paying such amount in cash, percentage		1.00%
Interest expense			$ 400,000	$ 600,000
Number of monthly installments | installment	10
Prepayment premium percentage	5.00%
Minimum liquidity floor	$ 5,000,000
Minimum principal amount pursuant to liquidity covenant	$ 15,000,000
Outstanding balance, net of unamortized issuance costs and unaccreted discount			18,400,000
Unamortized issuance costs and unaccreted discount			$ 1,100,000
Term loan | Minimum
Debt Instrument [Line Items]
Period for which company is entitled to make interest-only payments		30 months
Term loan | Maximum
Debt Instrument [Line Items]
Period for which company is entitled to make interest-only payments		36 months
Term loan, first tranche
Debt Instrument [Line Items]
Aggregate principal amount		$ 22,500,000
Net draw down proceeds		21,200,000
Closing costs		$ 1,300,000
Exercise price of warrant (in dollars per share) | $ / shares		$ 18.15
Number of shares of common stock for which warrant is exercisable (in shares) | shares		43,388
Additional debt discount recognized		$ 500,000
Term loan, second and third tranches
Debt Instrument [Line Items]
Warrant exercise price calculation, period immediately preceding relevant funding, number of trading days		5 days
Term loan, second and third tranches | Maximum
Debt Instrument [Line Items]
Exercise price of warrant (in dollars per share) | $ / shares		$ 18.15
Term loan, second tranche
Debt Instrument [Line Items]
Aggregate principal amount		$ 5,000,000
Term loan, third tranche
Debt Instrument [Line Items]
Aggregate principal amount		$ 7,500,000

Loans and Security Agreement _2

Loans and Security Agreement - Schedule of Principal Payments on Term Loan (Details) - Term loan - Term loan $ in Thousands	Mar. 31, 2022USD ($)
Debt Instrument [Line Items]
2022	$ 5,500
2023	6,000
2024	6,000
2025	2,000
Principal Payments	$ 19,500

Insurance Financing Note Paya_2

Insurance Financing Note Payable (Details) - 3.925% Note Payable - Notes Payable to Banks $ in Millions	Jul. 03, 2021USD ($)
Short-term Debt [Line Items]
Short-term note payable	$ 2
Interest rate, base percentage	3.93%
Amortization period (in months)	9 months

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent event	May 09, 2022	Apr. 08, 2022USD ($)	Jun. 30, 2022USD ($)	Apr. 06, 2022USD ($)customer
Subsequent Event [Line Items]
Largest customers | customer				2
Additional capital earned			$ 15,000,000	$ 15,000,000
Reverse stock split	0.09
Minimum
Subsequent Event [Line Items]
Reverse stock split	0.50
Maximum
Subsequent Event [Line Items]
Reverse stock split	0.07
Cantor Fitzgerald & Co
Subsequent Event [Line Items]
Sales agreement, threshold sale of shares		$ 12,200,000